Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Prognostic Models for Predicting Outcomes after Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin’s Disease: How Predictive Are They?.

Jose F. Leis, MD, PhD, Keith S. Hansen, MD, Peter T. Curtin, MD, Brandon M. Hayes-Lattin, MD, Keith S. Lanier, MD, Nathan R. Stanton, Charles D. Callaway, Ceder J. Fowler, Adam M. Dunn, Daniel Gruenberg, MD, Michael J. Mauro, MD, Gerald M. Segal, MD, Lisa K. Hansen, Jeffrey I. Menashe, MD, Tibor J. Kovacsovics, MD, Aleksandra Simic, MD, Richard T. Maziarz, MD.

Blood (2005) 106 (11): 5509.

https://doi.org/10.1182/blood.V106.11.5509.5509

Published: 2005

Journal Articles

Survival after Autologous Transplantation to Treat Diffuse Large B-Cell Lymphoma with a History of CNS Involvement, Bone Marrow Involvement, or Histologic Transformation.

Brandon Hayes-Lattin, MD, Pritesh Mehta, Adam Dunn, Nan Subbiah, Jose F. Leis, MD, PhD, Aleksandra Simic, MD, Bryon Allen, Suzanne Balliesen, Peter T. Curtin, MD, Elliot Epner, MD, PhD, William H. Fleming, MD, PhD, Carol Jacoby, Michael J. Mauro, MD, Craig R. Nichols, MD, Susan Schubach, Richard T. Maziarz, MD

Blood (2004) 104 (11): 5237.

https://doi.org/10.1182/blood.V104.11.5237.5237

Published: 2004

Journal Articles

Safety and Tolerability of Anti-Bacterial Prophylaxis during the Post-Engraftment Phase after Myeloablative Hematopoietic Stem Cell Transplantation.

Brandon Hayes-Lattin, MD, Joseph Bubalo, PharmD, Adam Dunn, Nan Subbiah, Bryon Allen, Suzanne Balleisen, Peter T. Curtin, MD, Carol Jacoby, Jose F. Leis, MD, PhD, Michael J. Mauro, MD, Aleksandra Simic, MD, Susan Schubach, Richard T. Maziarz, MD

Blood (2004) 104 (11): 5093.

https://doi.org/10.1182/blood.V104.11.5093.5093

Published: 2004

Journal Articles

A Randomized Phase II Study of Xcellerated T Cells™ with or without Prior Fludarabine Therapy in Patients with Relapsed or Refractory Multiple Myeloma.

James R. Berenson, MD, Ivan M. Borrello, MD, Ravi Vij, MD, Asad Bashey, MD, Thomas Martin, MD, Ralph V. Boccia, MD, Ann Mohrbacher, MD, Aleksandra Simic, MD, Gary Spitzer, MD, Jayne Meyer, Ron J. Berenson11, MD, Mark W. Frohlich12, MD

Blood (2004) 104 (11): 2410.

https://doi.org/10.1182/blood.V104.11.2410.2410

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Prognostic Models for Predicting Outcomes after Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin’s Disease: How Predictive Are They?.

Survival after Autologous Transplantation to Treat Diffuse Large B-Cell Lymphoma with a History of CNS Involvement, Bone Marrow Involvement, or Histologic Transformation.

Safety and Tolerability of Anti-Bacterial Prophylaxis during the Post-Engraftment Phase after Myeloablative Hematopoietic Stem Cell Transplantation.

A Randomized Phase II Study of Xcellerated T Cells™ with or without Prior Fludarabine Therapy in Patients with Relapsed or Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Update search

Prognostic Models for Predicting Outcomes after Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin’s Disease: How Predictive Are They?.

Survival after Autologous Transplantation to Treat Diffuse Large B-Cell Lymphoma with a History of CNS Involvement, Bone Marrow Involvement, or Histologic Transformation.

Safety and Tolerability of Anti-Bacterial Prophylaxis during the Post-Engraftment Phase after Myeloablative Hematopoietic Stem Cell Transplantation.

A Randomized Phase II Study of Xcellerated T Cells™ with or without Prior Fludarabine Therapy in Patients with Relapsed or Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only